Revenues in the second quarter surged 26 percent from 2004 totals for Quintiles, topping $537 million.

However, restructuring charges of $72 million related to the sale of its preclinical services, pharmaceutical sciences and clinical trials supplies business pushed losses to $44.2 million. The loss in the same period in 2004 was $10.1 million.

For details, see: